Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2019 08:00 ET | Source: Passage Bio

Passage Bio to Present at Upcoming Investor Conferences

PHILADELPHIA, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
September 23, 2019 08:00 ET | Source: Passage Bio

Passage Bio Grows Management Team with Chief Medical Officer and General Counsel Appointments

PHILADELPHIA, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
September 09, 2019 07:00 ET | Source: Passage Bio

Passage Bio Announces New Gene Therapy Development Program for Patients with Charcot-Marie-Tooth Neuropathy Type 2A

PHILADELPHIA, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS)...
September 04, 2019 08:00 ET | Source: Passage Bio

Passage Bio Closes $110 Million Series B Financing

PHILADELPHIA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS)...
September 03, 2019 08:00 ET | Source: Passage Bio

Passage Bio to Present at Morgan Stanley 17th Annual Global Healthcare Conference

PHILADELPHIA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
August 13, 2019 08:00 ET | Source: Passage Bio

Passage Bio Announces Launch of Natural History Study to Evaluate Patients with GM1 Gangliosidosis

PHILADELPHIA, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
August 06, 2019 08:00 ET | Source: Passage Bio

Passage Bio to Present at 2019 Wedbush PacGrow Healthcare Conference

PHILADELPHIA, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
July 25, 2019 08:00 ET | Source: Passage Bio

Passage Bio Expands Executive Management Team

PHILADELPHIA, July 25, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
July 10, 2019 08:00 ET | Source: Passage Bio

Passage Bio Announces New Dedicated Gene Therapy Manufacturing Suite

PHILADELPHIA, July 10, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
May 30, 2019 08:00 ET | Source: Passage Bio

Passage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising Gala

PHILADELPHIA, May 30, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...